8 Dermatology Headlines You Missed in September 2025
Summary: This monthly roundup from HCPLive compiles eight notable dermatology developments from September 2025. Topics include new FDA approvals (e.g., remibrutinib for chronic spontaneous urticaria, guselkumab for pediatric psoriasis, ruxolitinib cream in children), label expansions for therapies in epidermolysis bullosa, and research linking maternal diet and biologic therapy to dermatologic outcomes.
Key Highlights:
- FDA approved **remibrutinib** for chronic spontaneous urticaria, offering a new oral option.
- **Guselkumab (Tremfya)** received pediatric approval for plaque psoriasis in children age 6 and above.
- **Ruxolitinib cream** was approved for atopic dermatitis in children aged 2-11.
- **Beremagene geperpavec-svdt (Vyjuvek)** label updated to allow use from birth in dystrophic epidermolysis bullosa.
- Studies showed **maternal dietary diversity** is associated with reduced childhood eczema risk.
- A report pointed to **biologic therapy in psoriasis** correlating with lower malignancy risk.
- **Rocatinlimab** trials showed promising early results for treating atopic dermatitis.
- **Narrowband UVB phototherapy** was found effective for psoriasis in skin of color when other therapies weren’t tolerated.
Read the full article on HCPLive
Keywords:
Tim Smith,
Abigail Brooks,
dermatology headlines,
FDA approvals dermatology,
skin disease research